Systemic corticosteroids have been used extensively for 50 years in the management of inflammatory skin disorders and have become the mainstay of treatment for immunobullous disorders.1 Unfortunately, this treatment is associated with multiple potentially serious adverse effects. As a result, physicians have attempted to find efficacious corticosteroid-sparing agents to avoid the unwanted adverse effects of systemic corticosteroids. A recently published study2 demonstrated that high-potency topical corticosteroids were safer and more effective than systemic therapy in patients with bullous pemphigoid.
Hull CM, McKenna JK, Zone JJ. Topical Corticosteroids and Bullous Pemphigoid. Arch Dermatol. 2003;139(2):225. doi:10.1001/archderm.139.2.225-b
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.